Santaris Pharma A/S resumes full ownership of cancer programs licensed to Enzon Pharmaceutical Inc.

  Santaris Pharma A/S resumes full ownership of cancer programs licensed to
                          Enzon Pharmaceutical Inc.

  PR Newswire

  HOERSHOLM, Denmark and SAN DIEGO, Oct. 28, 2013

HOERSHOLM, Denmark and SAN DIEGO, Oct. 28, 2013 /PRNewswire/ -- Santaris
Pharma A/S, a clinical-stage biopharmaceutical company focused on the
discovery and development of RNA-targeted therapies, today announced that the
Company and its long term partner, Enzon Pharmaceutical Inc., have agreed that
all rights, data, products and intellectual properties relating to Enzon
Pharmaceutical Inc.'s LNA programs, developed under a license from Santaris
Pharma A/S, will revert to Santaris Pharma A/S. Further Enzon Pharmaceutical
Inc. will transfer an undisclosed amount to Santaris Pharma A/S.

(Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO )

Henrik Stage, President & CEO at Santaris Pharma A/S stated : "We have been
very pleased with the collaboration and are excited to resume full ownership
of these important cancer programs, of which several are under clinical
development."

About Locked Nucleic Acid (LNA) Drug Platform The LNA Drug Platform and Drug
Discovery Engine developed by Santaris Pharma A/S combines the company's
proprietary LNA chemistry with its highly specialized and targeted drug
development capabilities to rapidly deliver LNA-based drug candidates against
RNA targets, both mRNA and microRNA, for a range of diseases including
cardiometabolic disorders, infectious and inflammatory diseases, cancer and
rare genetic disorders. LNA is also sometimes referred to as BNA (Bicyclic or
Bridged Nucleic Acid). LNA-based drugs are a promising new class of
therapeutics that enable scientists to develop drugs that work through
previously inaccessible clinical pathways. The LNA Drug Platform overcomes the
limitations of earlier antisense and siRNA technologies to deliver
potent,single-stranded, LNA-based drug candidates across a multitude of
disease states. The unique combination of small size and very high affinity
allows this new class of drugs candidates to potently and specifically inhibit
RNA targets in many different tissues without the need for complex delivery
vehicles. The most important features of LNA-based drugs include excellent
specificity providing optimal targeting; increased affinity to targets
providing improved potency; and favorable pharmacokinetic and
tissue-penetrating properties that allow systemic delivery of these drugs
without complex and potentially troublesome delivery vehicles.

About Santaris Pharma A/S Santaris Pharma A/S is a privately held,
clinical-stage biopharmaceutical company focused on the discovery and
development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug
Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine
the company's proprietary LNA chemistry with its highly specialized and
targeted drug development capabilities to rapidly deliver potent
single-stranded LNA-based drug candidates across a multitude of disease
states. The company's research and development activities focus on infectious
diseases and cardiometabolic disorders, while partnerships with major
pharmaceutical companies address a range of therapeutic areas including
cancer, cardiovascular disease, infectious and inflammatory diseases, and rare
genetic disorders. The company has strategic partnerships with RaNA
Therapeutics, Bristol-Myers Squibb, miRagen Therapeutics, Shire plc., Pfizer,
GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent
estate, the company holds exclusive worldwide rights to manufacture and sell
products that comprise LNA as active ingredient for studies performed with a
view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is
headquartered in Denmark with operations in the United States. Please visit
www.santaris.com for more information.

Santaris Pharma A/S® is a registered trademark of Santaris Pharma A/S.
Santaris™, Santaris Pharma™ , Cureon™ and LNA-antimiR™ are trademarks of
Santaris Pharma A/S.

About Enzon Enzon Pharmaceuticals, Inc. is a biotechnology company that had
been dedicated to the research and development of innovative therapeutics for
patients with high unmet medical needs. Enzon receives royalty revenues on
seven marketed products that utilize its proprietary Customized PEGylation
Linker Technology (Customized Linker Technology®) platform, namely PegIntron®,
Sylatron®, Macugen®, CIMZIA®, OMONTYS®, Oncaspar and Adagen.

Further information about Enzon can be found on the Company's website at
www.enzon.com .

Website: http://www.santaris.com
Contact: Henrik Stage, President & CEO, Cell: +45-40260900, Company phone:
+45-45-17-98-88, e-mail: hs@santaris.com, www.santaris.com
 
Press spacebar to pause and continue. Press esc to stop.